Angiomyolipoma rebound tumor growth after discontinuation of everolimus in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis

INTRODUCTION: The EXIST-2 (NCT00790400) study demonstrated the superiority of everolimus over placebo for the treatment of renal angiomyolipomas associated with tuberous sclerosis complex (TSC) or sporadic lymphangioleiomyomatosis (LAM). This post hoc analysis of EXIST-2 study aimed to assess angiom...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:PLoS One
Autori principali: Bissler, John J., Nonomura, Norio, Budde, Klemens, Zonnenberg, Bernard A., Fischereder, Michael, Voi, Maurizio, Louveau, Anne-Laure, Herbst, Fabian, Bebin, E. Martina, Curatolo, Paolo, Zonta, Andrea, Belousova, Elena
Natura: Artigo
Lingua:Inglês
Pubblicazione: Public Library of Science 2018
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6128468/
https://ncbi.nlm.nih.gov/pubmed/30192751
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0201005
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi